Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT163
- Development stage
- Phase 1
- Lead developer
- BioNTech
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
BNT163 is an investigational mRNA-based vaccine developed for the prevention of genital lesions caused by herpes simplex virus type 2 (HSV-2), and potentially also HSV-1. The vaccine encodes three non-infectious HSV-2 glycoproteins designed to induce a broad immune response targeting multiple viral antigens. This approach aims to prevent HSV cellular entry and spread, as well as counteract the immunosuppressive properties of herpes simplex viruses. BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter clinical trials. As of late 2022, it entered Phase 1 clinical development in healthy volunteers and individuals with recurrent genital herpes[1][2][3][4][5][6][7].
02
Targets
gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on BNT163.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT163.